previous compound ID: 2744 next compound
InChIKey: YQZBAXDVDZTKEQ-UHFFFAOYSA-N
SMILES: CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl.C(CC(=O)O)C(=O)O

biological descriptors:

CFTR relevance: unspecified

Category:
Influence on CFTR function unknown
Order of interaction unknown
subcellular compartment unknown

reference list:

ReferenceID: 53
"J Goepp" "DY Thomas" "E Matthes" "B Kus" "J Liao" "SD Macknight" "GW Carlile" "JW Hanrahan" "D Rotin" "R Robert"

chemical graph of compound 2744





CID is 71399
synonyms found at PubChem are:
Loxapine succinate, 27833-64-3, Loxapine succinate salt, Loxapac, Cloxazepin, Daxolin, Lederle, Loxapine (succinate), UNII-X59SG0MRYU, Loxapine,succinate, Loxapine, Succinate, CCRIS 1917, EINECS 248-682-0, X59SG0MRYU, CL 71563, CPD000058470, MLS000069383, NCGC00016160-02, SMR000058470, Loxitane (TN), CAS-27833-64-3, 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate, 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine succinate (1:1), DSSTox_CID_25227, DSSTox_RID_80764, DSSTox_GSID_45227, C22H24ClN3O5, CL-71563, W-107092, CHEBI:6549, 1977-10-2 (Parent), Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1), Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1), Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1), Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1), AZ-004, SR-01000002971, Loxapine succinate [USAN], Loxapine succinate [USAN:USP], Staccato-loxapine, butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine, Loxipine Succinate, Prestwick_304, Lopac-L-106, AC1Q5VQU, Opera_ID_1518, Loxapine succinate (USP), SCHEMBL41643, MLS000758291, MLS001146961, MLS001401432, MLS002222201, SPECTRUM2300242, Loxapine succinate salt, solid, REGID_for_CID_71399, AC1L2G38, CHEMBL1201155, DTXSID3045227, CTK4G0318, AOB5330, MolPort-003-666-776, ZX-AFC001324, HMS1568K06, HMS1922L14, HMS2051E05, HMS2093N20, HMS2095K06, HMS2232N05, HMS3262O21, HMS3374F02, HMS3393E05, HMS3652O10, HMS3712K06, Pharmakon1600-02300242, Tox21_110311, Tox21_500720, AZ-104, CCG-39497, HY-17390A, MFCD00069298, NSC759578, s4086, AKOS015994711, Tox21_110311_1, CS-4285, KS-1083, LP00720, NC00011, NSC-759578, VA11204, NCGC00016160-01, NCGC00016160-03, NCGC00016160-04, NCGC00016160-05, NCGC00021145-11, NCGC00094068-01, NCGC00094068-02, NCGC00094068-03, NCGC00261405-01, O287, SAM001247061, LS-147408, EU-0100720, FT-0653022, VU0239541-8, D00794, 833L643, C-54162, SR-01000002971-2, SR-01000002971-6, SR-01000002971-9, 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, Succinate, Loxapine succinate, United States Pharmacopeia (USP) Reference Standard, (E)-2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine succinate, 2-Chloro-11-(4-methyl-1- piperazinyl)-dibenz[b,f][1,4]- oxazepine succinate, butanedioic acid; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine, 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine butanedioic acid